These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 34285711)

  • 1. Exploring the Mystery of Angiotensin-Converting Enzyme II (ACE2) in the Battle against SARS-CoV-2.
    Sharma D; Sharma J; Singh A
    J Renin Angiotensin Aldosterone Syst; 2021; 2021():9939929. PubMed ID: 34285711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
    Shukla AK; Banerjee M
    High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin-converting enzyme 2, coronavirus disease 2019, and abdominal aortic aneurysms.
    Xu B; Li G; Guo J; Ikezoe T; Kasirajan K; Zhao S; Dalman RL
    J Vasc Surg; 2021 Nov; 74(5):1740-1751. PubMed ID: 33600934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the SARS-CoV-2 receptorACE2 in human heart is associated with uncontrolled diabetes, obesity, and activation of the renin angiotensin system.
    Herman-Edelstein M; Guetta T; Barnea A; Waldman M; Ben-Dor N; Barac YD; Kornowski R; Arad M; Hochhauser E; Aravot D
    Cardiovasc Diabetol; 2021 Apr; 20(1):90. PubMed ID: 33906662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ACE2: from protection of liver disease to propagation of COVID-19.
    Warner FJ; Rajapaksha H; Shackel N; Herath CB
    Clin Sci (Lond); 2020 Dec; 134(23):3137-3158. PubMed ID: 33284956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting enzyme 2 and COVID-19 in cardiorenal diseases.
    Sharma RK; Li J; Krishnan S; Richards EM; Raizada MK; Mohandas R
    Clin Sci (Lond); 2021 Jan; 135(1):1-17. PubMed ID: 33399851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epithelial and Endothelial Expressions of ACE2: SARS-CoV-2 Entry Routes.
    Guney C; Akar F
    J Pharm Pharm Sci; 2021; 24():84-93. PubMed ID: 33626315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multifunctional angiotensin converting enzyme 2, the SARS-CoV-2 entry receptor, and critical appraisal of its role in acute lung injury.
    Oz M; Lorke DE
    Biomed Pharmacother; 2021 Apr; 136():111193. PubMed ID: 33461019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of ACE inhibitors and angiotensin type II blockers with ACE2 overexpression in COVID-19 comorbidities: A pathway-based analytical study.
    Parit R; Jayavel S
    Eur J Pharmacol; 2021 Apr; 896():173899. PubMed ID: 33508281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Two-Way Switch Role of ACE2 in the Treatment of Novel Coronavirus Pneumonia and Underlying Comorbidities.
    Pang XC; Zhang HX; Zhang Z; Rinkiko S; Cui YM; Zhu YZ
    Molecules; 2020 Dec; 26(1):. PubMed ID: 33396184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Origin and genomic characteristics of SARS-CoV-2 and its interaction with angiotensin converting enzyme type 2 receptors, focusing on the gastrointestinal tract.
    Galanopoulos M; Doukatas A; Gazouli M
    World J Gastroenterol; 2020 Nov; 26(41):6335-6345. PubMed ID: 33244196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection.
    Verdecchia P; Cavallini C; Spanevello A; Angeli F
    Eur J Intern Med; 2020 Jun; 76():14-20. PubMed ID: 32336612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [ACE-inhibitors, angiotensin receptor blockers and severe acute respiratory syndrome caused by coronavirus].
    Verdecchia P; Reboldi G; Cavallini C; Mazzotta G; Angeli F
    G Ital Cardiol (Rome); 2020 May; 21(5):321-327. PubMed ID: 32310915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target.
    Al-Zaidan L; Mestiri S; Raza A; Merhi M; Inchakalody VP; Fernandes Q; Taib N; Uddin S; Dermime S
    Tumour Biol; 2021; 43(1):177-196. PubMed ID: 34420993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor.
    Oz M; Lorke DE; Kabbani N
    Pharmacol Ther; 2021 May; 221():107750. PubMed ID: 33275999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of Angiotensin-Converting Enzyme 2: A Potential Target to Prevent COVID-19?
    Hu Y; Liu L; Lu X
    Front Endocrinol (Lausanne); 2021; 12():725967. PubMed ID: 34745001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor utilization of angiotensin-converting enzyme 2 (ACE2) indicates a narrower host range of SARS-CoV-2 than that of SARS-CoV.
    Wang Q; Qiu Y; Li JY; Liao CH; Zhou ZJ; Ge XY
    Transbound Emerg Dis; 2021 May; 68(3):1046-1053. PubMed ID: 32794346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
    Kuba K; Yamaguchi T; Penninger JM
    Front Immunol; 2021; 12():732690. PubMed ID: 35003058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Classical and alternative receptors for SARS-CoV-2 therapeutic strategy.
    Masre SF; Jufri NF; Ibrahim FW; Abdul Raub SH
    Rev Med Virol; 2021 Sep; 31(5):1-9. PubMed ID: 33368788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 Cellular Entry Is Independent of the ACE2 Cytoplasmic Domain Signaling.
    Karthika T; Joseph J; Das VRA; Nair N; Charulekha P; Roji MD; Raj VS
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.